Calidi Biotherapeutics (CLDI) Competitors $5.01 -0.75 (-13.02%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$5.15 +0.14 (+2.79%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDI vs. MGX, EXOZ, WHWK, VXRT, EPIX, ANRO, JMAC, BYSI, ELUT, and SRZNShould you be buying Calidi Biotherapeutics stock or one of its competitors? The main competitors of Calidi Biotherapeutics include Metagenomi (MGX), eXoZymes (EXOZ), Whitehawk Therapeutics (WHWK), Vaxart (VXRT), ESSA Pharma (EPIX), Alto Neuroscience (ANRO), Maxpro Capital Acquisition (JMAC), BeyondSpring (BYSI), Elutia (ELUT), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry. Calidi Biotherapeutics vs. Its Competitors Metagenomi eXoZymes Whitehawk Therapeutics Vaxart ESSA Pharma Alto Neuroscience Maxpro Capital Acquisition BeyondSpring Elutia Surrozen Metagenomi (NASDAQ:MGX) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations. Which has preferable earnings and valuation, MGX or CLDI? Calidi Biotherapeutics has lower revenue, but higher earnings than Metagenomi. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetagenomi$52.29M1.37-$78.06M-$2.11-0.91Calidi BiotherapeuticsN/AN/A-$29.22MN/AN/A Does the media favor MGX or CLDI? In the previous week, Calidi Biotherapeutics had 2 more articles in the media than Metagenomi. MarketBeat recorded 3 mentions for Calidi Biotherapeutics and 1 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.00 beat Calidi Biotherapeutics' score of -0.67 indicating that Metagenomi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Calidi Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Do analysts recommend MGX or CLDI? Metagenomi presently has a consensus target price of $13.00, suggesting a potential upside of 577.08%. Given Metagenomi's stronger consensus rating and higher probable upside, equities research analysts clearly believe Metagenomi is more favorable than Calidi Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders hold more shares of MGX or CLDI? 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. 17.8% of Metagenomi shares are owned by insiders. Comparatively, 6.7% of Calidi Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is MGX or CLDI more profitable? Calidi Biotherapeutics has a net margin of 0.00% compared to Metagenomi's net margin of -172.21%. Calidi Biotherapeutics' return on equity of 0.00% beat Metagenomi's return on equity.Company Net Margins Return on Equity Return on Assets Metagenomi-172.21% -31.21% -22.21% Calidi Biotherapeutics N/A N/A -344.45% Which has more volatility & risk, MGX or CLDI? Metagenomi has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. SummaryMetagenomi beats Calidi Biotherapeutics on 7 of the 13 factors compared between the two stocks. Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLDI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDI vs. The Competition Export to ExcelMetricCalidi BiotherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$15.16M$293.03M$5.50B$20.71BDividend YieldN/AN/A4.59%3.65%P/E RatioN/AN/A30.0528.06Price / SalesN/A462.25456.5355.98Price / CashN/A22.4424.8417.60Price / Book-2.168.908.524.61Net Income-$29.22M-$115.81M$3.27B$994.05M7 Day Performance-29.27%-2.79%6.13%1.97%1 Month Performance-58.17%-8.25%0.07%-1.60%1 Year Performance-76.01%-4.32%36.43%14.32% Calidi Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDICalidi Biotherapeutics0.232 of 5 stars$5.01-13.0%N/A-76.0%$15.16MN/A0.0038MGXMetagenomi2.5906 of 5 stars$2.27-3.4%$13.00+472.7%-33.3%$84.85M$52.29M-1.08236News CoverageUpcoming EarningsEXOZeXoZymesN/A$10.10-0.2%N/AN/A$84.54M$70K0.0029News CoverageWHWKWhitehawk TherapeuticsN/A$1.79+1.1%N/AN/A$84.33M$27.78M11.1940News CoveragePositive NewsEarnings ReportAnalyst DowngradeVXRTVaxart2.7071 of 5 stars$0.37-8.5%$3.00+721.9%-34.5%$83.55M$47.40M-1.35120News CoverageUpcoming EarningsEPIXESSA Pharma1.4925 of 5 stars$1.88+0.5%$2.00+6.4%-58.8%$83.45MN/A-2.9850Upcoming EarningsANROAlto Neuroscience1.645 of 5 stars$3.08+1.0%$8.50+176.0%-63.4%$83.38MN/A-1.32N/ANews CoverageUpcoming EarningsJMACMaxpro Capital AcquisitionN/A$6.14-3.6%N/A+3,517.0%$82.45MN/A0.002,021BYSIBeyondSpringN/A$2.03+1.0%N/A+3.1%$81.85M$1.75M0.0080Upcoming EarningsGap DownELUTElutia3.5397 of 5 stars$1.96+6.5%$8.00+308.2%-33.0%$80.60M$24.38M-1.02180Positive NewsSRZNSurrozen2.7598 of 5 stars$9.39+1.5%$38.50+310.0%+33.7%$80.38M$10.65M-0.3880News CoverageEarnings ReportUpcoming Earnings Related Companies and Tools Related Companies Metagenomi Competitors eXoZymes Competitors Whitehawk Therapeutics Competitors Vaxart Competitors ESSA Pharma Competitors Alto Neuroscience Competitors Maxpro Capital Acquisition Competitors BeyondSpring Competitors Elutia Competitors Surrozen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CLDI) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLDI Stock Alerts